Zhenyi Medical Secures Over RMB 1 Billion in Series C Funding, Focused on Cardiovascular Disease Solutions

Investment Circle (ID: pedaily2012) November 28th, by reporter, recently, a platform-based interventional innovation enterprise focusing on "blood flow management" - Jiangsu Trulive Medtech Co., Ltd. (referred to as “Trulive") officially announced the completionSeries C Financing of Several Hundred Million YuanTrulive Medical successfully completes one round of financing every year.This round of financing was jointly completed by multiple institutions, including Oriental Fortune, Guoyuan Equity, Xiamen Industry Investment/Venture Capital, Xiamen Gold Innovation, Bozheng Capital, Siming Sci-Tech Innovation, and existing shareholder Life Tree Capital.

Since its establishment in 2019, Trulive has consistently focused on the field of cardiovascular diseases, which have extremely high mortality and disability rates, and where there is still a gap in the Chinese market. Particularly in the field of structural heart disease, where clinical needs are urgent and the competitive landscape has yet to solidify—specifically in the mitral and tricuspid valve sectors—Trulive has built a differentiated advantage by innovatively proposing a "1+1>2" synergistic development strategy. By simultaneously developing product pipelines for both mitral and tricuspid valves, covering both repair and replacement technologies, Trulive has formed a rare full-scenario solution capability in China, along with a leading toolbox product system in the country. This meets the diverse treatment needs of patients with different conditions and anatomical structures, effectively filling the gap in high-end medical devices in China for interventional treatments of mitral and tricuspid valves.

For this round of financing,Trulive Chairman Wen Jing"This successful financing holds profound strategic significance for Trulive, marking a critical opportunity for the company to break through and enter a new stage of development. With several innovative products launching successively and subsequent products advancing at an accelerated pace, we urgently need to comprehensively establish a nationwide base network. On one hand, we will focus on Shanghai as our R&D core, building a high-end production cluster in the Yangtze River Delta region, while gradually establishing innovation centers and production bases in key areas across China. Through multi-base collaboration, we aim to achieve efficient resource integration and full market coverage, further solidifying Trulive's technological leadership and industrialization capabilities in the cardiovascular intervention field. At the same time, leveraging China’s high-quality clinical resources, we will create specialized education and operation centers, which will serve as a pivot to address global cardiovascular health needs. We will actively explore new paths for international medical cooperation, expedite the advancement of our global strategic layout, and promote the overseas expansion of our products."

Relevant Responsible Person of Oriental FortuneStated: "Trulive's development philosophy of 'one step ahead in technology, half a step ahead in business' aligns closely with our investment logic. The company implements a tiered strategy: on one hand, relying on its platform to continuously launch cash-flow products made in China, filling domestic gaps; on the other hand, using differentiated technology to create exclusive cornerstone products and globally innovative products, building core competitive barriers. With its platform-based R&D capabilities and commercial execution, product iteration is fast, long-term growth potential is strong, and it has the potential for sustained excess returns. We are optimistic about the company’s future prospects and look forward to working together for progress."

Guoyuan Equity Related Responsible PersonStated: "This round of investment in Trulive is based on the company's outstanding innovation capabilities in the cardiovascular intervention field—multiple products fill the gap in domestically produced options, overcoming 'bottleneck' technical challenges, gaining high clinical recognition, and making solid commercial progress. The company has a clear IPO path and demonstrates strong competitiveness for going public in terms of R&D strength, product pipeline, and strategic layout. We are optimistic about the company’s long-term value and will fully leverage Guoyuan’s professional advantages in capital operations, resource integration, and IPO guidance to support Trulive in efficiently advancing its IPO process, achieving a leapfrog development from an excellent innovative enterprise to a publicly listed company."

Relevant responsible persons from Xiamen Industrial Investment and Xiamen Venture CapitalStated: "As the first investment project of Xiamen City's Cardiovascular Industry Fund, we highly value Trulive. The company leverages the strong clinical resources of Xiamen University Affiliated Cardiovascular Hospital to build robust innovation technology and achievement transformation capabilities, establishing a professional education and international marketing platform. It has successfully promoted the dissemination and popularization of cutting-edge technologies both domestically and internationally, laying the foundation for global expansion. This round of support stems from deep recognition of its technological barriers, team strength, and global ambition. We firmly believe that Trulive will undoubtedly emerge in the international cardiovascular device field and grow into a leading enterprise with both global influence and industrial value."

Relevant Responsible Person of Xiamen Cardiovascular Industry FundStated: "The Xiamen Cardiovascular Industry Fund, initiated by Xiamen Industrial Investment, Xiamen Venture Capital, and the Affiliated Cardiovascular Hospital of Xiamen University, is the first industrial fund in China participated by a public hospital and focused on cardiovascular healthcare. It aims to build an innovative incubation system featuring 'government funding guidance—capital empowerment—clinical validation—industrial implementation.' This investment not only provides capital support but also empowers from multiple dimensions such as technology, clinical practice, and industry. We look forward to collaborating with Trulive to further improve the cardiovascular industry ecosystem and inject innovative vitality into the development of Xiamen's cardiovascular health industry."

Relevant responsible persons from Xiamen-Jinmen Innovation and Siming Sci-Tech InnovationStated: "Our investment this time not only reflects our confidence in Trulive's technical barriers and commercial prospects in the field of structural heart disease, but also our endorsement of its strategic plan to 'root itself in China while facing the world.' We will mobilize the full-chain resources of 'clinical-research-capital-industry' in Xiamen to provide financial support and ecosystem synergy for the company, helping to accelerate the establishment of its R&D center and product iteration. Together, we aim to create a 'Xiamen model' for the cardiovascular medical industry."

Borz Capital Related Responsible PersonStated: "Trulive, with its solid R&D foundation, has successfully built a comprehensive technology platform, achieving a diversified pipeline layout in the cardiovascular intervention field and demonstrating strong product line extensibility and systematic innovation capabilities. We particularly recognize Trulive's continuous dedication to addressing unmet clinical needs through innovative concepts and rapid transformation capabilities, and we hope to jointly push China's high-end cardiovascular interventional treatment to new heights in the future."